PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 04 07 2018
revised: 22 02 2019
accepted: 02 05 2019
pubmed: 9 5 2019
medline: 9 4 2020
entrez: 9 5 2019
Statut: ppublish

Résumé

Although tumorigenesis is dependent on the reprogramming of cellular metabolism, the metabolic pathways engaged in the formation of metastases remain largely unknown. The transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) plays a pleiotropic role in the control of cancer cell metabolism and has been associated with a good prognosis in prostate cancer. Here, we show that PGC1α represses the metastatic properties of prostate cancer cells via modulation of the polyamine biosynthesis pathway. Mechanistically, PGC1α inhibits the expression of c-MYC and ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme for polyamine synthesis. Analysis of

Identifiants

pubmed: 31064849
pii: 0008-5472.CAN-18-2043
doi: 10.1158/0008-5472.CAN-18-2043
pmc: PMC7293888
mid: NIHMS1591815
doi:

Substances chimiques

Biomarkers, Tumor 0
Dicarboxylic Acid Transporters 0
MYC protein, human 0
Mitochondrial Membrane Transport Proteins 0
PPARGC1A protein, human 0
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha 0
Polyamines 0
Proto-Oncogene Proteins c-myc 0
SLC25A21 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3268-3280

Subventions

Organisme : NCI NIH HHS
ID : R00 CA194192
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Nature. 2017 Jul 6;547(7661):109-113
pubmed: 28658205
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9
pubmed: 18268112
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8
pubmed: 8356088
Cell Metab. 2017 Nov 7;26(5):778-787.e5
pubmed: 28988825
Oncotarget. 2016 Nov 22;7(47):77071-77086
pubmed: 27776343
Oncogenesis. 2016 Jan 18;5:e188
pubmed: 26779810
J Biol Chem. 2000 May 26;275(21):16302-8
pubmed: 10748020
Immunity. 2011 Dec 23;35(6):871-82
pubmed: 22195744
Mol Endocrinol. 2009 Jun;23(6):772-83
pubmed: 19264843
Mol Endocrinol. 2010 Jan;24(1):114-27
pubmed: 19884383
Clin Cancer Res. 2000 May;6(5):1736-43
pubmed: 10815892
Oncogene. 2008 Jun 5;27(25):3576-86
pubmed: 18212742
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209
pubmed: 25248858
FEBS J. 2015 Feb;282(4):647-72
pubmed: 25495651
J Med Chem. 1978 Jan;21(1):50-5
pubmed: 619149
Nat Protoc. 2012 Apr 12;7(5):872-81
pubmed: 22498707
Cancer Res. 1994 Jun 15;54(12):3210-7
pubmed: 8205541
Mol Cancer Ther. 2015 Feb;14(2):586-96
pubmed: 25527635
Cancer Res. 2000 Sep 15;60(18):5125-33
pubmed: 11016639
Oncogene. 2013 Jul 25;32(30):3483-90
pubmed: 23208510
Cancer Res. 2009 Aug 1;69(15):6149-57
pubmed: 19622763
Eur J Cancer Clin Oncol. 1987 Aug;23(8):1103-7
pubmed: 3115786
Cell Metab. 2012 Jan 4;15(1):110-21
pubmed: 22225880
Trends Cancer. 2016 Oct;2(10):619-631
pubmed: 28607951
Genes Dev. 2008 Jul 15;22(14):1948-61
pubmed: 18628400
Tumour Biol. 2017 Apr;39(4):1010428317695031
pubmed: 28381162
Gut. 2016 Feb;65(2):286-95
pubmed: 25792707
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
Nat Cell Biol. 2016 Jun;18(6):645-656
pubmed: 27214280
Science. 2013 Mar 15;339(6125):1323-8
pubmed: 23429703
Mol Endocrinol. 1999 Dec;13(12):2151-62
pubmed: 10598588
Sci Transl Med. 2019 Jan 30;11(477):
pubmed: 30700572
Future Oncol. 2017 Apr;13(9):809-819
pubmed: 28125906
Mol Cell Biol. 1999 Jan;19(1):1-11
pubmed: 9858526
Clin Cancer Res. 2003 Mar;9(3):981-90
pubmed: 12631596
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Cancer Res. 2000 Jan 1;60(1):28-34
pubmed: 10646846
Cell Metab. 2010 Dec 1;12(6):633-42
pubmed: 21109195
Front Endocrinol (Lausanne). 2015 May 26;6:83
pubmed: 26074877
Mol Cell Endocrinol. 2007 Jan 29;264(1-2):128-41
pubmed: 17157980
Mod Pathol. 1997 Nov;10(11):1113-9
pubmed: 9388062
Cancer Res. 1997 Feb 1;57(3):524-31
pubmed: 9012485
Nature. 2016 Sep 15;537(7620):422-426
pubmed: 27580028
Am J Cancer Res. 2019 Feb 01;9(2):198-211
pubmed: 30906622
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63
pubmed: 9192621
Cancer Res. 2008 Dec 1;68(23):9735-45
pubmed: 19047152
Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15
pubmed: 25241037

Auteurs

Lisa Kaminski (L)

Université Côte d'Azur, Inserm U1065, C3M, France.

Stéphanie Torrino (S)

Université Côte d'Azur, Inserm U1065, C3M, France.

Maeva Dufies (M)

Biomedical Department, Centre Scientifique de Monaco, Principality of Monaco.

Zied Djabari (Z)

Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.

Romain Haider (R)

Université Côte d'Azur, Inserm U1065, C3M, France.
Department of Urology, Hôpital Pasteur 2, CHU Nice, Université Côte d'Azur, France.

François-René Roustan (FR)

Université Côte d'Azur, Inserm U1065, C3M, France.
Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.

Emilie Jaune (E)

Université Côte d'Azur, Inserm U1065, C3M, France.

Kathiane Laurent (K)

Université Côte d'Azur, Inserm U1065, C3M, France.

Nicolas Nottet (N)

Université Côte d'Azur, Inserm U1065, C3M, France.

Jean-François Michiels (JF)

Department of Pathology, Hôpital Pasteur 2, CHU Nice, Université Côte d'Azur, France.

Maeva Gesson (M)

Université Côte d'Azur, Inserm U1065, C3M, France.

Stéphane Rocchi (S)

Université Côte d'Azur, Inserm U1065, C3M, France.

Nathalie M Mazure (NM)

Université Côte d'Azur, Inserm U1065, C3M, France.

Matthieu Durand (M)

Department of Urology, Hôpital Pasteur 2, CHU Nice, Université Côte d'Azur, France.

Jean-François Tanti (JF)

Université Côte d'Azur, Inserm U1065, C3M, France.

Damien Ambrosetti (D)

Department of Pathology, Hôpital Pasteur 2, CHU Nice, Université Côte d'Azur, France.

Stephan Clavel (S)

Université Côte d'Azur, Inserm U1065, C3M, France.

Issam Ben-Sahra (I)

Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.

Frédéric Bost (F)

Université Côte d'Azur, Inserm U1065, C3M, France. bost@unice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH